ArticleAmerican journal of translational research2023
Prognostic value of multiple immune inflammatory markers in diffuse large B-cell lymphoma.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- Prognostic value of the CONUT score in newly diagnosed diffuse large B-cell lymphoma.Oncology letters · 2026Article
- Validation of prognostic models in elderly patients with diffuse large B-cell lymphoma in a real-world nationwide population-based study - development of a clinical nomogram.Annals of hematology · 2025Article
- An analysis of the relationship of triglyceride glucose index with diffuse large B-cell lymphoma prognosis: a retrospective study.Frontiers in endocrinology · 2025Article
- Evaluation of the incidence, predictors, risk assessment scores and outcomes of thromboembolism in a cohort of Egyptian NHL patients - Real World Experience.Annals of hematology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the prognostic value of multiple immune inflammatory indicators for diffuse large B-cell lymphoma (DLBCL).
methodsThe clinical data of 175 patients with DLBCL who were diagnosed and received Immunochemotherapy in The Qinzhou First People's Hospital between January 2015 and December 2021 were retrospectively analyzed for this study. Patients were classified into a death group (n = 54) and a survival group (n = 121) depending on their prognosis. The clinical data of the patients with lymphocytes-to-beads (LMR), neutrophils-to-lymphocytes (NLR), and platelets-to-lymphocytes (PLR) were collected. The receiver operator characteristic curve (ROC) was used to determine the optimal critical value of the immune index. The Kaplan-Meier was used to draw the survival curve. The Cox regression model was used to analyze the factors affecting the prognosis of DLBCL. A nomogram risk prediction model was constructed to verify its effectiveness.
resultsBy the ROC curve analysis, the optimal cut-off value was 3.93 × 10
conclusionIPI score, neutrophil count, NLR, and PLR are risk factors impacting the prognosis of DLBCL. The combined prediction of IPI score, neutrophil count, NLR, and PLR can better reflect the prognosis of DLBCL. It can be used as a clinical index to predict the prognosis of diffuse large B-cell lymphoma, and provide clinical basis for improving the prognosis of patients.
Indexed as
Identifiers
37193185PMC10182499W4376871922What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.